ENVB RSI Chart
Last 7 days
-5.6%
Last 30 days
-4.5%
Last 90 days
1.2%
Trailing 12 Months
-76.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2020 | 38.8M | 36.1M | 35.4M | 0 |
2019 | 42.6M | 42.6M | 41.1M | 39.9M |
2018 | 47.3M | 46.1M | 44.2M | 43.0M |
2017 | 41.5M | 47.1M | 49.5M | 48.6M |
2016 | 23.0M | 25.7M | 31.3M | 36.1M |
2015 | 16.8M | 16.8M | 16.9M | 20.4M |
2014 | 6.1M | 11.5M | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 22, 2024 | coveney kevin michael | acquired | - | - | 60,000 | chief financial officer |
Feb 22, 2024 | facchini peter j. | acquired | - | - | 50,000 | chief innovation officer |
Feb 22, 2024 | tucker joseph edward | acquired | - | - | 100,000 | chief executive officer |
Sep 15, 2023 | pasqualone frank | bought | 2,140 | 2.14 | 1,000 | - |
Mar 13, 2023 | coveney kevin michael | acquired | - | - | 26,500 | chief financial officer |
Jan 25, 2023 | facchini peter j. | acquired | - | - | 17,000 | chief innovation officer |
Jan 25, 2023 | tucker joseph edward | acquired | - | - | 44,000 | chief executive officer |
Jan 25, 2023 | hagel jillian marie | acquired | - | - | 12,000 | vice president of innovation |
Jan 25, 2023 | kanubaddi avani | acquired | - | - | 10,000 | president and coo |
Oct 13, 2021 | tucker joseph edward | acquired | - | - | 16,374 | chief executive officer |
Which funds bought or sold ENVB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | unchanged | - | - | 1.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | -30.00 | 100 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -354,900 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -3.13 | -4,199 | 12,277 | -% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 15,397 | 15,397 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 40,104 | 40,104 | -% |
May 14, 2024 | AdvisorShares Investments LLC | added | 68.39 | 54,450 | 238,833 | 0.04% |
May 13, 2024 | NATIONAL BANK OF CANADA /FI/ | unchanged | - | -25.00 | 63.00 | -% |
May 13, 2024 | UBS Group AG | added | 49,730 | 4,970 | 4,983 | -% |
May 13, 2024 | HRT FINANCIAL LP | new | - | 63,000 | 63,000 | -% |
Unveiling Enveric Biosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Enveric Biosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Enveric Biosciences, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 |
Revenue | 2.8% | 8.00 | 8.00 | 10.00 | 9.00 | 9.00 | 11.00 | 11.00 | 10.00 | 11.00 | 11.00 | 11.00 | 11.00 | 13.00 | 12.00 | 12.00 | 12.00 | 10.00 | 7.00 | 7.00 | 8.00 | 4.00 |
Cost Of Revenue | 2.5% | 7.00 | 6.00 | 8.00 | 7.00 | 7.00 | 9.00 | 9.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 | 10.00 | 10.00 | 9.00 | 12.00 | 8.00 | 5.00 | 2.00 | 4.00 | 3.00 |
Gross Profit | 3.8% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 | 3.00 | 1.00 |
Operating Expenses | -36.2% | 0.00 | 1.00 | 1.00 | 4.00 | 3.00 | 4.00 | 3.00 | 13.00 | -3.75 | 3.00 | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | -40.5% | 0.00 | 1.00 | 1.00 | -6.78 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | 24.2% | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 48.4% | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Income Taxes | -259.3% | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 6.00 | 0.00 | - | - | -2.39 | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 36.4% | -0.99 | -1.56 | -1.77 | -2.13 | 0.00 | -1.24 | -1.89 | -13.44 | 6.00 | -1.26 | -1.57 | -3.42 | -4.06 | -3.26 | - | - | - | - | - | - | - |
Net Income | 30.9% | -0.57 | -0.82 | -1.10 | 1.00 | 0.00 | -1.26 | -1.86 | -19.77 | 6.00 | -1.26 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 105.8% | 9.00 | 4.00 | 7.00 | 10.00 | 16.00 | 20.00 | 31.00 | 29.00 | 32.00 | 27.00 | 70.00 | 24.00 | 26.00 | 4.00 | 28.00 | 28.00 | 28.00 | 29.00 | 30.00 | 27.00 | 31.00 |
Current Assets | 129.8% | 8.00 | 4.00 | 6.00 | 9.00 | 15.00 | 18.00 | 22.00 | 19.00 | 23.00 | 18.00 | 22.00 | 22.00 | 23.00 | 2.00 | 11.00 | 10.00 | 10.00 | 0.00 | 9.00 | 11.00 | 11.00 |
Cash Equivalents | -100.0% | - | 2.00 | 4.00 | 7.00 | 13.00 | 18.00 | 21.00 | 18.00 | 22.00 | 17.00 | 21.00 | 21.00 | 23.00 | 2.00 | 3.00 | 2.00 | 1.00 | 0.00 | 2.00 | 2.00 | 2.00 |
Net PPE | -10.9% | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 | 2.00 | 9.00 | - | - | - | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 |
Liabilities | - | - | - | - | - | - | 4.00 | 7.00 | 6.00 | 8.00 | 4.00 | 14.00 | 5.00 | 7.00 | 11.00 | 15.00 | 15.00 | 18.00 | 2.00 | 19.00 | 14.00 | 19.00 |
Current Liabilities | 1.0% | 2.00 | 2.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 14.00 | 13.00 | 17.00 | 2.00 | 14.00 | 14.00 | 15.00 |
Shareholder's Equity | 231.3% | 6.00 | 2.00 | 2.00 | 5.00 | 10.00 | 15.00 | 23.00 | 22.00 | 24.00 | 22.00 | 55.00 | 19.00 | 19.00 | 3.00 | 13.00 | 13.00 | 10.00 | 11.00 | 13.00 | 11.00 | 11.00 |
Retained Earnings | -2.5% | -98.96 | -96.50 | -93.06 | -90.24 | -83.89 | -79.21 | -70.53 | -68.05 | -65.26 | -60.74 | -18.63 | -15.92 | -15.01 | -11.76 | -45.16 | -44.09 | -42.41 | -4.89 | -37.81 | -37.87 | -36.44 |
Additional Paid-In Capital | 5.1% | 106 | 101 | 96.00 | 96.00 | 95.00 | 94.00 | 94.00 | 90.00 | 89.00 | 83.00 | 74.00 | 35.00 | 34.00 | 15.00 | 58.00 | 57.00 | 53.00 | 3.00 | 50.00 | 48.00 | 47.00 |
Accumulated Depreciation | 9.6% | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 166.3% | 7.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 7.00 | - | - | - | 11.00 | - | - | - | 51.00 | - | - | - | 7.00 | - | - | - | 16.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -48.4% | -2,598 | -1,751 | -2,740 | -4,465 | -5,137 | -3,462 | -4,550 | -4,585 | -4,548 | -4,067 | -2,206 | -2,021 | -3,162 | -2,249 | -393 | -351 | -893 | 826 | - | -490 | -984 |
Share Based Compensation | -3.6% | 351 | 365 | 373 | 880 | 533 | 529 | 645 | 678 | 769 | 7,768 | 487 | 751 | 3,592 | - | - | - | - | - | - | - | - |
Cashflow From Investing | 100.0% | - | -38* | 20* | 17.00 | -5.17 | -6.19 | -18.57 | -53.89 | -505 | -189 | 3,055 | - | -675 | 2.00 | -6.17 | 3.00 | -43.37 | -56.63 | - | -115 | -111 |
Cashflow From Financing | 3678.1% | 6,658 | -186 | -105 | -1,052 | - | -1* | 7,824 | 958 | 9,398 | 7* | -9* | 18.00 | 24,882 | 3,599 | 228 | 493 | 1,212 | -1,371 | - | 484 | 1,448 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
General and administrative | $ 1,933,753 | $ 2,948,400 |
Research and development | 458,155 | 1,825,792 |
Depreciation and amortization | 85,409 | 86,486 |
Total operating expenses | 2,477,317 | 4,860,678 |
Loss from operations | (2,477,317) | (4,860,678) |
Other (expense) income | ||
Change in fair value of warrant liabilities | 10,039 | 50,657 |
Change in fair value of investment option liability | 11,398 | 119,505 |
Change in fair value of derivative liability | 13,000 | |
Interest income (expense), net | 696 | (11) |
Total other income | 22,133 | 183,151 |
Net loss before income taxes | (2,455,184) | (4,677,527) |
Income tax expense | (1,731) | |
Net loss | (2,456,915) | (4,677,527) |
Less preferred dividends attributable to non-controlling interest | 12,329 | |
Less deemed dividends attributable to accretion of embedded derivative at redemption value | 110,991 | |
Net loss attributable to shareholders | (2,456,915) | (4,800,847) |
Other comprehensive loss | ||
Foreign currency translation | 17,906 | 1,968 |
Comprehensive loss | $ (2,439,009) | $ (4,798,879) |
Net loss per share - basic | $ (0.61) | $ (2.31) |
Net loss per share - diluted | $ (0.61) | $ (2.31) |
Weighted average shares outstanding, basic | 4,001,456 | 2,078,271 |
Weighted average shares outstanding, diluted | 4,001,456 | 2,078,271 |
Condensed Consolidated Balance Sheet - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 6,356,036 | $ 2,287,977 |
Prepaid expenses and other current assets | 1,872,786 | 1,293,554 |
Total current assets | 8,228,822 | 3,581,531 |
Other assets: | ||
Property and equipment, net | 452,228 | 507,377 |
Intangible assets, net | 168,744 | 210,932 |
Total other assets | 620,972 | 718,309 |
Total assets | 8,849,794 | 4,299,840 |
Current liabilities: | ||
Accounts payable | 1,852,833 | 1,218,783 |
Accrued liabilities | 487,464 | 1,075,643 |
Investment option liability | 12,210 | 23,608 |
Warrant liability | 15,431 | 25,470 |
Total current liabilities | 2,367,938 | 2,343,504 |
Commitments and contingencies (Note 8) | ||
Mezzanine equity | ||
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Total mezzanine equity | ||
Shareholders’ equity | ||
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common stock, $0.01 par value, 100,000,000 shares authorized, 7,294,005 and 2,739,315 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 72,939 | 27,392 |
Additional paid-in capital | 105,917,193 | 100,815,851 |
Stock subscription receivable | (1,817,640) | |
Accumulated deficit | (98,956,433) | (96,499,518) |
Accumulated other comprehensive loss | (551,843) | (569,749) |
Total shareholders’ equity | 6,481,856 | 1,956,336 |
Total liabilities, mezzanine equity, and shareholders’ equity | $ 8,849,794 | $ 4,299,840 |